Cutting to the chase: How pathogenic mutations cause Alzheimer’s by Wolfe, Michael S.
Cutting to the chase: How pathogenic
mutations cause Alzheimer’s
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Wolfe, Michael S. 2015. “Cutting to the chase: How pathogenic
mutations cause Alzheimer’s.” The Journal of Experimental
Medicine 212 (12): 1991. doi:10.1084/jem.21212insight4. http://
dx.doi.org/10.1084/jem.21212insight4.
Published Version doi:10.1084/jem.21212insight4
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320218
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
INSIGHTS
1988 INSIGHTS | The Journal of Experimental Medicine
Development of pancreatic ductal adenocarcinoma (PDAC) is known to be driven by a per-
sistent inflammatory state, as oncogenic mutations alone are not sufficient for tumorigenesis. 
Toll-like receptors (TLRs), the pillars of the innate immune system, are highly expressed in 
the tumor microenvironment and on circulating leukocytes in PDAC. Contrasting re-
sults have reported antitumorigenic effects or induction of intrapancreatic inflammation and 
tumor progression upon ligation of different members of this receptor family.
TLR9 in particular is expressed in both tumor and tumor-related cells, and its activation has 
been shown to impair tumor cell proliferation, suggesting that TLR9 agonists might be useful 
as adjuvant therapy. In this issue, Zambirinis et al. further examined the specific role of 
TLR9 signaling in PDAC. Gain- and loss-of-function experiments in a mouse model of PDAC 
showed that TLR9 activation is oncogenic in PDAC. Interestingly, these effects are only partially explained by activation of TLR9 
signaling in the tumor cells themselves. Unexpectedly, the authors found expression of TLR9 on pancreatic stellate cells 
(PSCs; myofibroblast-like cells in the pancreas) and showed that TLR9 activation in these cells results in the production of the 
CCL3 and CCL11 chemokines. They show for the first time that CCL11 can promote the proliferation of pancreatic cancer cells 
in a dose-dependent manner. Activation 
of TLR9 in PSCs also leads to the recruit-
ment of tumor suppressive regulatory 
T cells (T regs) that, together with TLR9-
activated myeloid-derived suppressor cells 
(MDSCs), favor the generation of an 
immunosuppressive microenvironment.
Perhaps one of the most important 
aspects of the crosstalk between tumor 
cells and their microenvironment is the 
inhibition of anticancer immune re-
sponses. This new study provides com-
pelling evidence that, in addition to the 
adaptive immune system, specific mol-
ecules in the innate immune system, 
such as TLR9, can play crucial roles in 
cancer development. Importantly, the 
recent development of small molecule 
agonists and antagonists of TLRs may 
offer a new strategy to inhibit cancer 
growth. It will be interesting to determine 
how such manipulations may be com-
bined with other strategies to activate anti-
tumor T cells. Another exciting aspect of 
this work is the prominent role of PSCs, 
providing further support to the notion 
that desmoplasia from fibroblasts plays 
a critical role in the recruitment and 
(in)activation of immune infiltrates in 
pancreatic cancer. Unquestionably, the 
molecular complexity of tumor, stroma, 
and immune cells will continue to engage 
the efforts of pancreatic cancer researchers 
for many years to come.
Zambirinis, C.P., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20142162 
Pancreatic cancer takes its Toll
Insight from Pawel Mazur (left) 
and Julien Sage (right)
Schematic depicts specific effects of TLR9 activation in epithelial, stromal, and inflammatory 
compartments in PDAC. A proposed model of tumor-promoting effects of TLR9 activation 
in pancreas tumorigenesis identifies PSCs as a key component of the inflammatory process. 
TLR9-activated PSCs mediate their protumorigenic effects on the epithelial compartment 
via CCL11 secretion. In addition, TLR9 activation may generate an immunosuppressive 
microenvironment by promoting MDSC proliferation and indirectly increasing T reg numbers 
via CCL3 secretion, both critical to disable cytotoxic T cells (CTL) in PDAC.
Pawel K. Mazur and Julien Sage, Stanford University: pmazur@stanford.edu and julsage@stanford.edu
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Tumors are aberrant organ systems that develop through cooption of developmental and wound response 
programs. Wnt signaling represents a central organizing force in organ development and healing, but con-
stitutive Wnt activation initiates and maintains tumor growth. Development of molecular targeted therapies 
against Wnt has proven challenging because of the diversity of ligands, receptors, and effectors.
In this issue, Ladang et al. discover that ELP3, an enzymatic component of Elongator, promotes Wnt-
induced colon tumorigenesis and recovery from injury. As its name implies, the Elongator complex critically 
regulates transcriptional elongation through RNA polymerase II, but Elongator also functions in translation 
through tRNA modification, cytoplasmic kinase signaling, and exocytosis. Leveraging previous studies of 
oncogenic activity of Elongator, the authors found that Wnt induces ELP3 and that ELP3 levels are increased 
in colon cancers, a cancer commonly associated with Wnt dysregulation. Targeted disruption of ELP3 in the 
colon ablated Tuft cell generation, but no significant phenotype in colon organization or animal health was detectable at baseline. 
In contrast, loss of ELP3 severely attenuated tumor initiation and recovery from radiation injury, potentially through translation—
not transcriptional—control of SOX9, a master organizer of the endodermal cellular hierarchy.
The colon undergoes continuous renewal with replacement of the colonic epithelium every seven days on average. Upon 
injury, like radiation, Wnt signaling is activated to accelerate self-renewal. The current study suggests that Elongator activity is 
necessary for injury responses in the colon, although future studies may define whether Elongator is sufficient for recovery of 
the colon and other tissues dependent on Wnt. Conceptually, activating Elongator could accelerate regeneration or improve 
the efficacy of cell-based therapies. As ELP3 is the catalytic subunit of the histone acetyltransferase elongator complex, its activity 
may be amenable to disruption through pharmacologic antagonists. Targeting ELP3 in the colon had minimal detrimental 
effects, suggesting that ELP3 may be an attractive target in Wnt-related cancers, especially in the colon where orally administered 
therapies could provide locoregional antagonism.
Ladang, A., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20142288
Jeremy Rich, Lerner Research Institute, Cleveland Clinic: richj@ccf.org
Lending an ‘ELPing hand to tumor initiation
Insight from 
Jeremy Rich
(A) A healthy intestinal crypt is illustrated in the left panel. Upon inactivation of the Apc gene suppressor ("Oncogenic hit"), Wnt signaling is 
constitutively activated and triggers adenoma development. Whereas the acetylase ELP3 is dispensable for the maintenance of normal stem cells 
and intestinal homeostasis, this factor is required for Wnt-dependent tumor initiation and induction of cancer stem cell self-renewal. 
(B) The inactivation of Apc triggers β-catenin stabilization and consequently drives the expression of Wnt target genes, such as SOX9 and ELP3. 
ELP3 chemically modifies tRNAs to promote SOX9 translation. As a result, a pool of Lgr5+/Dclk1+/Sox9+ cells efficiently drives Wnt-dependent 
tumor initiation in the intestine.
INSIGHTS
1990 INSIGHTS | The Journal of Experimental Medicine
Both T cells and NK cells employ complex networks of transcriptional regulators to control 
their differentiation and functional prowess. In this issue, three studies report that the trans-
cription factor ZEB2 is critical for generation and expansion of terminally differentiated effector 
cells, chiefly by working in partnership with T-bet.
Several transcription factors have been shown to regulate CD8+ T cell differentiation during 
an immune response. T-bet has emerged as a driving force in the development of KLRG1hi 
terminal effector cells. Both Dominguez et al. and Omilusik et al. show here that ZEB2, 
a molecule not previously associated with lymphocyte differentiation, is strongly up-regulated 
in early KLRG1hi effector cells and supports their progression to a short-lived effector status—
yet appears dispensable for generation of long-lived memory cells. T-bet is required for ZEB2 
expression, and the factors coregulate many of the same genes. However, the impact of ZEB2 deficiency could not be completely 
overcome by T-bet overexpression, and both cooperative and independent activities of these factors may be important.
Interestingly, van Helden et al. demonstrate a parallel role for ZEB2 in permitting NK cell maturation. Zeb2 deficiency 
thwarted normal NK cell differentiation, migration into peripheral tissues, and control of melanoma growth. Again, many of 
these features echo the role of T-bet in NK cell development, and there was ample evidence of cooperation between the factors 
in controlling gene expression; however, ZEB2 was not completely subservient to T-bet because ZEB2 could partially restore 
NK development in T-bet gene–deficient mice.
These studies characterize ZEB2 as a novel player in the transcriptional control of lymphocyte differentiation, playing strikingly 
similar roles in CD8+ T cells and NK cells. Numerous phenotypic and functional changes accompany the differentiation of 
lymphocytes—a challenge has been to understand how these differentiation states relate to complex transcriptional networks 
within the cell and how generation of 
a stable subset is achieved. ZEB2 is 
downstream of T-bet, but cooperation 
between these factors is crucial for reg-
ulation of multiple genes—hence ZEB2 
may serve to reinforce the differentiation 
program initiated by T-bet expression. 
However, whereas both ZEB2 and T-bet 
inhibit expression of memory precursor-
associated genes in CD8+ T cells, 
Dominguez, et al. suggest that low level 
ZEB2 expression is required for genera-
tion of the CD8+ T cell effector-memory 
subset, indicating a more nuanced role. 
Also, whereas ZEB2 does not appear 
necessary for acquisition of key effector functions (such as cytolysis and IFN-γ production) by terminally differentiated CD8+ 
T cells or mature NK cells, it will be important to see how this factor impacts pathogen control in various contexts. Deciphering 
the pathways that promote effector cell generation may help direct strategies for better vaccine approaches, and understanding 
the cooperative and independent roles of T-bet and Zeb2 could provide new targets for therapeutic intervention.
Dominguez, C.X., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20150186 
Omilusik, K.D., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20150194 
van Helden, M.J., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20150809 
It takes Zeb2 to tango: Cooperation between T-bet and Zeb2 is essential for CD8+ T cell 
effector differentiation and NK cell development. Although increasing T-bet expression alone 
can mediate some of the necessary gene expression changes, coordination with Zeb2 (which 
is itself under T-bet transcriptional control) is required for full commitment and expansion of 
terminally differentiated CD8+ T cells and mature NK cells.
Sara E. Hamilton and Stephen C. Jameson, Center for Immunology, University of Minnesota: hamil062@umn.edu and james024@umn.edu
Effective effector generation of CD8+ T cells and NK cells:  
A need for T-bet and ZEB-too
Insight from Sara Hamilton (left) 
and Stephen Jameson (right)
JEM Vol. 212, No. 12 1991
How dominant mutations in presenilin (PSEN) cause early-onset familial Alzheimer’s disease (FAD) has been 
debated since the discovery of such mutations 20 years ago. A study by Szaruga et al. in this issue of JEM now 
appears to provide a definitive answer.
Presenilin is the catalytic subunit of γ-secretase, a protease that cuts the transmembrane domain of 
the amyloid precursor protein (APP) to produce the C terminus of the amyloid β-peptide (Aβ) that 
notoriously deposits in the Alzheimer brain. Some argue that reduction of presenilin’s proteolytic activ-
ity (i.e., a loss-of-function effect) is responsible for the neurodegeneration caused by FAD mutations. 
Others have shown that some mutations do not reduce proteolytic activity, but all increase the propor-
tion of aggregation-prone 42-residue Aβ (Aβ42) to 40-residue Aβ (Aβ40; i.e., a gain of toxic function). 
Further complicating matters, γ-secretase initially cuts APP substrate via an endopeptidase activity to 
produce Aβ48 and Aβ49 and release the corresponding APP intracellular domain (AICD). These long 
Aβ peptides are then sequentially trimmed via a carboxypeptidase function of γ-secretase along two primary pathways: 
Aβ49 → Aβ46 → Aβ43 → Aβ40 and Aβ48 → Aβ45 → Aβ42 → Aβ38.
To address the loss- versus gain-of-function question, Szaruga et al. examined γ-secretase proteolytic activity in samples from 
post-mortem human brains from 24 FAD mutation carriers, covering nine different PSEN mutations. The samples contained 
endogenous human γ-secretase complexes and—importantly—both wild-type and PSEN mutant complexes. Under these 
natural conditions associated with the human disease state, the production of AICD—a measure of γ-secretase endoprotease activ-
ity—was not significantly different from that seen in control non-AD brains. Thus, the presence of the wild-type PSEN allele 
apparently compensates for any loss of 
endoproteolytic activity from the mutant 
allele. In contrast, clear reduction of car-
boxypeptidase activity—as measured by 
the ratio of Aβ38 from its precursor 
Aβ42—was seen for every mutation.
These findings have implications for 
the mechanism of Alzheimer pathogen-
esis and for drug discovery. In considering 
γ-secretase as a therapeutic target, one 
should first know what specific functional 
alterations in the enzyme lead to dis-
ease, and that appears to be decreased 
carboxypeptidase activity. Therefore, a 
search for stimulators of this activity would 
make sense. Such compounds have al-
ready been identified, although they 
appear to stimulate only the Aβ42 → Aβ38 
step, insufficient if other long Aβ pep-
tides are augmented in Alzheimer’s and 
play pathogenic roles. As is so often the 
case, answering one key question leads 
to another.
Szaruga, M., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20150892 
Ab is derived from its precursor protein APP by sequential proteolysis, first by β-secretase 
(not depicted) and then by γ-secretase, the latter hydrolyzing within the transmembrane (TM) 
domain. Initial cleavage occurs at the so-called ε site (indicated by the scissors), releasing the 
APP intracellular domain or AICD (red intracellular piece) and leaving Aβ49 or Aβ48 fragments 
in the membrane. Aβ49 or Aβ48 fragments are successively cut by the carboxypeptidase-like 
activity of γ-secretase, increasing the probability of release from the plasma membrane to the 
extracellular medium. Both ε cleavage and carboxypeptidase TM trimming depend on PSEN, 
the catalytic subunit of γ-secretase. Pathogenic mutations in PSEN cause a qualitative shift 
in Aβ profile production, increasing the proportion of released longer Aβ peptides, which are 
prone to aggregate and form the plaques observed FAD.
Michael S. Wolfe, Brigham and Women’s Hospital and Harvard Medical School: mswolfe@partners.org
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